Association of finasteride with prostate cancer
| Autor: | Yonghua Lei, Yanyao Gao, Ruixiao Li, Qisheng Tang, Dong Wang, Bo Zhang, Dong Cui, Lei Wang, He Wang, Yu Chen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry General Medicine Cochrane Library Institutional review board medicine.disease Placebo 03 medical and health sciences Prostate cancer chemistry.chemical_compound 0302 clinical medicine Systematic review chemistry 030220 oncology & carcinogenesis Internal medicine Meta-analysis Finasteride Medicine Prostate Cancer Prevention Trial 030212 general & internal medicine business |
| Zdroj: | Medicine. 99:e19486 |
| ISSN: | 1536-5964 0025-7974 |
| Popis: | Background The Prostate Cancer Prevention Trial has shown a protective effect of finasteride on prostate cancer, but it also showed that finasteride can increase the risk of high-grade prostate cancer. Several studies have investigated the relationship between finasteride and prostate cancer, but these studies have shown inconsistent results. Ethics The protocol was approved by the institutional review board of each study center. Written informed consent will be obtained from all patients before registration, in accordance with the Declaration of Helsinki. Methods We performed a systematic literature review and meta-analysis to assess the association between finasteride and prostate cancer. Systematic literature searches were conducted using PubMed, EMBASE, Science Direct/Elsevier, MEDLINE, CNKI, and the Cochrane Library up to October 2018 to identify studies that involved the relationship between finasteride and prostate cancer. Meta-analysis was performed using Review Manager and Stata software. Combined ORs were identified with 95% confidence intervals (95% CI) in a random or fixed effects model. Results Eight studies were identified, including 54,335 cases of patients that used finasteride and 9197 patients who served as placebo controls. Our results illustrate that there is a significant correlation between finasteride use and prostate cancer with combined ORs of 0.70 [0.51, 0.96]. A significant correlation between finasteride use and high-grade prostate cancer was also observed with combined ORs of 2.10 [1.85, 2.38]. Conclusions This study confirms that finasteride significantly reduced the risk of prostate cancer; however, the malignant degree of prostate cancer was increased. Studies with larger sample sizes are needed to better clarify the correlation between finasteride use and prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|